SLC5A2 and type 2 diabetes mellitus: In the last few years, the introduction in the therapeutic armamentarium of Sodium Glucose Transporter-2 inhibitors (SGLT2-i) has dramatically modified the renal risk of T2DM patients, mainly due to the hemodynamic and anti-albuminuric properties of these drugs.